Acuta Capital Partners, LLC Taysha Gene Therapies, Inc. Call Options Transaction History
Acuta Capital Partners, LLC
- $98.8 Million
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding TSHA
# of Institutions
119Shares Held
136MCall Options Held
25.9KPut Options Held
24K-
Avoro Capital Advisors LLC New York, NY18.7MShares$39.5 Million0.56% of portfolio
-
Rtw Investments, LP New York, NY14.9MShares$31.7 Million0.48% of portfolio
-
Black Rock Inc. New York, NY11.7MShares$24.9 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA10.9MShares$23 Million0.3% of portfolio
-
Vr Adviser, LLC New York, NY9MShares$19.1 Million1.87% of portfolio
About Taysha Gene Therapies, Inc.
- Ticker TSHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,359,500
- Market Cap $103M
- Description
- Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...